Special Issue

Decoding Cancer Signals Using Liquid Biopsy

Message from the Guest Editors

Liquid biopsy is revolutionizing oncology practice as a minimally invasive and easily repeatable way to detect cancer-associated changes in the genome, transcriptome, epigenome, and proteome. These advancements provide tools to understand cancer biology, inform clinical decisions and monitor treatment responses. We welcome authors to contribute articles for this Special Issue that highlight the recent and upcoming advancements in the uses of liquid biopsies in oncology treatments and cancer care. Articles may address any single circulating analyte or multi-analyte approach using any biological fluid, such as plasma, serum, urine, and cerebrospinal fluid (CSF), among others. We will accept both original research papers outlining breakthrough discoveries and review papers outlining current developments in liquid biopsies.

Guest Editors

Dr. Fatima Shadma

- 1. Department of Medical Oncology, Ingham Institute of Applied Medical Research, Liverpool, NSW 2170, Australia
- 2. School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2031, Australia
- 3. School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia

Dr. Fatemeh Vafaee

- 1. School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2031, Australia
- UNSW Data Science Hub, University of New South Wales, Sydney, NSW 2031, Australia

Deadline for manuscript submissions

closed (5 August 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/144555

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

